These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 638014)

  • 21. Study of the mechanism of Corynebacterium parvum anti-tumour activity. I. Protective effect on the growth of two syngeneic tumours.
    Mazurek C; Chalvet H; Stiffel CL; Biozzi G
    Int J Cancer; 1976 Apr; 17(4):511-7. PubMed ID: 946965
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Active specific immunotherapy of mouse methylcholanthrene induced tumours with Corynebacterium parvum and irradiated tumour cells.
    Bomford R
    Br J Cancer; 1975 Nov; 32(5):551-7. PubMed ID: 1082344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumour growth, phagocytic activity and antibody response in Corynebacterium parvum-treated mice.
    Woodruff MF; McBride WH; Dunbar N
    Clin Exp Immunol; 1974 Jul; 17(3):509-18. PubMed ID: 4549691
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The distribution and persistence in vivo of Corynebacterium parvum in relation to its antitumor activity.
    Scott MT; Milas L
    Cancer Res; 1977 Jun; 37(6):1673-9. PubMed ID: 870181
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of intracerebral administration of Corynebacterium parvum on the growth of brain tumors in mice.
    Kiya K; Toge T; Harada K; Uozumi T; Hattori T
    Gan; 1981 Jun; 72(3):446-50. PubMed ID: 7319201
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemo-immunotherapy of mouse tumours using cyclophosphamide and C. parvum.
    Scott MT
    Dev Biol Stand; 1977 Apr 13-15; 38():307-10. PubMed ID: 608516
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The antitumour activity of maltose tetrapalmitate compared with other immunoadjuvants, and its effectiveness after tumour surgery.
    El Kappany H; Chopra C; Nigam VN; Brailovsky CA; Elhilali M
    Br J Cancer; 1980 Nov; 42(5):703-11. PubMed ID: 7459208
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Further observations on the inhibition of tumor growth by Corynebacterium parvum with cyclophosphamide. III. Effect of C. parvum on cyclophosphamide metabolism.
    Fisher B; Wolmark N; Rubin H
    J Natl Cancer Inst; 1976 Jul; 57(1):225-6. PubMed ID: 1003505
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antitumor activity of Corynebacterium parvum and retinyl palmitate used in combination on the Lewis lung carcinoma.
    Pavelic ZP; Dave S; Bialkowski S; Priore RL; Greco WR
    Cancer Res; 1980 Dec; 40(12):4617-21. PubMed ID: 7438095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of dose and schedule of immune stimulant on efficacy of combination Corynebacterium parvum-cyclophosphamide treatment for a murine mammary adenocarcinoma.
    Purnell DM; Bartlett GL; Kreider JW
    Cancer Res; 1979 Jan; 39(1):1-5. PubMed ID: 761179
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biological effects of Corynebacterium parvum. 3. Amplification of resistance and impairment of active immunity to murine tumours.
    Smith SE; Scott MT
    Br J Cancer; 1972 Oct; 26(5):361-7. PubMed ID: 4343677
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Local control and disease-free survival after treatment of a squamous cell carcinoma by Corynebacterium parvum and local irradiation.
    Suit HD; Sedlacek R; Silobrcic V
    Cancer Res; 1977 Nov; 37(11):3869-75. PubMed ID: 908026
    [No Abstract]   [Full Text] [Related]  

  • 33. Comparative antitumor effects of Corynebacterium parvum, Bordetella pertussis, Bacillus Calmette-Guérin, and levamisole alone or in combination with cyclophosphamide in the CaD2 murine mammary adenocarcinoma system.
    Purnell DM; Bartlett GL; Kreider JW; Biro TG; Kontra J
    Cancer Res; 1979 Dec; 39(12):4838-42. PubMed ID: 498111
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Experimental cancer immunotherapy: comparison of tumor rejection if F344 rats given live Mycobacterium bovis (Strain BCG) and killed Corynebacterium parvum.
    Likhite VV
    J Natl Cancer Inst; 1976 May; 56(5):985-9. PubMed ID: 994209
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunopotentiation of cell-mediated hypersensitivity by Corynebacterium parvum (Propionibacterium acnes).
    Maguire HC; Cipriano D
    Int Arch Allergy Appl Immunol; 1983; 70(1):34-9. PubMed ID: 6848475
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Active experimental inhibition of cancer by corynebacterium parvum.
    Wrba H; Dutter A
    Osterr Z Onkol; 1977 Oct; 4(2-3):60-1. PubMed ID: 579449
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Further observations on the effect of C. parvum and anti-tumour globulin on syngeneically transplanted mouse tumours.
    Woodruff MF; Inchley MP; Dunbar N
    Br J Cancer; 1972 Apr; 26(2):67-76. PubMed ID: 5038327
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms of anti-tumor action of Corynebacterium parvum. I. Potentiated tumor-specific immunity and its therapeutic limitations.
    Dye ES; North RJ; Mills CD
    J Exp Med; 1981 Sep; 154(3):609-20. PubMed ID: 6974214
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of the combination of Corynebacterium parvum and levamisole on murine tumors.
    Anaclerio A; Conti G; Moras ML; Barale C; Spreafico F
    Eur J Cancer (1965); 1977 Dec; 13(12):1451-53. PubMed ID: 413718
    [No Abstract]   [Full Text] [Related]  

  • 40. Surgery plus Corynebacterium parvum immunotherapy for Lewis lung carcinoma in mice.
    Karrer K; Rella W; Goldin A
    Eur J Cancer (1965); 1979 Jun; 15(6):867-73. PubMed ID: 499275
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.